ESC 365 - Cardiovascular risk according to add-on therapy in patients with type 2 diabetes

ESC Premium Access

Cardiovascular risk according to add-on therapy in patients with type 2 diabetes

Session: Poster Session 3 - Diabetes, adiposity and metabolic syndrome

Topic: Epidemiology

Speaker: Mr D. Aagaard (Copenhagen, DK)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Mr David Thein Aagaard

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

0 follower

8 more presentations in this session

Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events

Speaker: Doctor M. Husain (Toronto, CA)

Vascular endothelial growth factor-C and mortality in patients with diabetes and suspected coronary artery disease: from the ANOX study

Speaker: Doctor T. Unoki (Kumamoto, JP)

Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a propensity score-matched study

Speaker: Professor B. Yan (Hong Kong, CN)

The combined treatment with glucagon like peptide-1 analogues and sodium-glucose co-transporter 2 causes a greater improvement of arterial stiffness than each treatment alone in type 2 diabetes .

Speaker: Doctor I. Ikonomidis (Athens, GR)

Lentiviral transfer of interleukin 4 gene to 3T3-L1 adipocytes prevents development of lipid-induced insulin resistance

Speaker: Ms S. Michurina (Moscow, RU)

Access the full session

Poster Session 3 - Diabetes, adiposity and metabolic syndrome

Speakers: Mr D. Aagaard, Doctor M. Husain, Doctor T. Unoki, Professor B. Yan, Doctor I. Ikonomidis...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources